Variable name;level;Overall;Yes;No;p;test
;n;1351;450;900;;
Age;[0 -30);95;72 (75.8);23 (24.2);<0.001;
;[30 -35);247;175 (70.9);72 (29.1);;
;[35 -40);457;164 (35.9);293 (64.1);;
;40+;550;39 (7.1);511 (92.9);;
Age (mean);;38.7 [34.9, 41.6];34.5 [31.2, 37.2];40.5 [37.6, 42.3];<0.001;nonnorm
Number of children;0;374;234 (62.7);139 (37.3);<0.001;
;1;276;99 (35.9);177 (64.1);;
;More than 1;701;117 (16.7);584 (83.3);;
BMI;<18.5;78;29 (37.2);49 (62.8);0.002;
;18.5-24.9;809;304 (37.6);505 (62.4);;
;25-29.9;254;89 (35.2);164 (64.8);;
;>=30;106;20 (18.9);86 (81.1);;
BMI (mean);;22.6 [20.4, 25.4];22.3 [20.3, 24.9];22.7 [20.6, 25.9];0.005;nonnorm
Treatment center;Curie Paris;813;289 (35.5);524 (64.5);0.039;
;Curie St Cloud;537;161 (30);376 (70);;
Year BC diagnosis;2011;161;24 (14.9);137 (85.1);<0.001;
;2012;190;31 (16.3);159 (83.7);;
;2013;186;52 (28);134 (72);;
;2014;225;70 (31.1);155 (68.9);;
;2015;221;109 (49.3);112 (50.7);;
;2016;217;97 (44.7);120 (55.3);;
;2017;149;67 (45);82 (55);;
Genetic analysis;No;651;132 (20.3);519 (79.7);<0.001;
;Yes;700;318 (45.5);381 (54.5);;
Hereditary predisposition;No;543;239 (44.1);303 (55.9);0.189;
;Yes;142;72 (50.7);70 (49.3);;
Inflammatory BC;No;1332;446 (33.5);886 (66.5);0.450;
;Yes;18;4 (22.2);14 (77.8);;
Clinical Tumor size (mm);;30.2 (21.5);31.4 (20.3);29.6 (22.1);0.162;
Clinical T stage (TNM);T0-T1;588;182 (31);406 (69);0.087;
;T2;589;216 (36.7);373 (63.3);;
;T3-T4;165;51 (30.9);114 (69.1);;
Clinical N stage (TNM);N0;853;285 (33.4);568 (66.6);1.000;
;N1-N2-N3;489;164 (33.5);325 (66.5);;
SBR grade;Grade I;58;16 (27.6);42 (72.4);0.006;
;Grade II;524;151 (28.8);373 (71.2);;
;Grade III;758;280 (36.9);478 (63.1);;
BC subtype;Luminal;703;208 (29.6);495 (70.4);0.020;
;TNBC;242;92 (38.2);149 (61.8);;
;HER2+/HR+;195;76 (39);119 (61);;
;HER2+/HR-;81;28 (34.6);53 (65.4);;
Histological type;NST;1259;428 (34);831 (66);0.014;
;Lobular;53;8 (15.1);45 (84.9);;
;Others;37;14 (37.8);23 (62.2);;
Neoajuvant chemotherapy;No;740;203 (27.4);537 (72.6);<0.001;
;Yes;610;247 (40.5);363 (59.5);;
Chemotherapy setting;Adjuvant;740;203 (27.4);537 (72.6);<0.001;
;NAC;609;246 (40.4);363 (59.6);;
